The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment

C. J. Hoekstra, S. G. Stroobants, O. S. Hoekstra, J. Vansteenkiste, B. Biesma, F. J.H.M. Schramel, N. Van Zandwijk, H. Van Tinteren, E. F. Smit

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

75 Citaten (Scopus)

Samenvatting

Combined modality treatment (CMT) for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) is at present studied extensively. To select patients with truly stage IIIA-N2 disease, however, proves to be difficult with current diagnostic tests. Distant metastases may become clinically overt during induction chemotherapy (IC) or shortly after, revealing the inaccuracies of current staging algorithms. A prospective study with [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) in IIIA-N2 NSCLC patients was performed to assess its value in the selection of this patient group. Fifty-seven patients received a whole body FDG PET scan as part of an ongoing response monitoring trial. Results were compared with conventional staging. In 32/57 (56%) PET suggested upstaging, which was confirmed in 17/57 (30%) with a median follow-up of 16 (range 2-49) months. These results show that using the conventional staging algorithm a substantial group of patients was understaged. FDG PET improves the selection of patients suitable for CMT.

Originele taal-2Engels
Pagina's (van-tot)151-157
Aantal pagina's7
TijdschriftLung Cancer
Volume39
Nummer van het tijdschrift2
DOI's
StatusGepubliceerd - 1 feb. 2003
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment'. Samen vormen ze een unieke vingerafdruk.

Citeer dit